SpringerLink
Log in

A promising drug for neuropathic pain: identification of vesicular nucleotide transporter as a novel target of eicosapentaenoic acid

  • Journal Club
  • Published:
Purinergic Signalling Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable.

References

  1. Kato Y et al (2022) Vesicular nucleotide transporter is a molecular target of eicosapentaenoic acid for neuropathic and inflammatory pain treatment. Proc Natl Acad Sci USA 119(30):e2122158119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tsuda M et al (2003) P2X(4) receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 424(6950):778–783

    Article  CAS  PubMed  Google Scholar 

  3. Tozaki-Saitoh H et al (2008) P2Y(12) receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 28(19):4949–4956

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yu TT et al (2019) P2Y12 regulates microglia activation and excitatory synaptic transmission in spinal lamina II neurons during neuropathic pain in rodents. Cell Death Dis 10(3):165

  5. Gu N et al (2016) Microglial P2Y12 receptors regulate microglial activation and surveillance during neuropathic pain. Brain Behav Immun 55:82–92

    Article  CAS  PubMed  Google Scholar 

  6. Masuda T et al (2016) Dorsal horn neurons release extracellular ATP in a VNUT-dependent manner that underlies neuropathic pain. Nat Commun 7:12529

  7. Matsuzaki M et al (2009) Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease - secondary prevention analysis from JELIS. Circ J 73(7):1283–1290

    Article  CAS  PubMed  Google Scholar 

  8. Marchioli R et al (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction - time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105(16):1897–1903

    Article  CAS  PubMed  Google Scholar 

  9. Serhan CN et al (2008) Anti-inflammatory and proresolving lipid mediators. Ann Rev Pathol-Mechanisms Dis 3:279–312

    Article  CAS  Google Scholar 

  10. Chapkin RS et al (2009) Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids 81(2–3):187–191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Moore RA et al (2015) Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database Syst Rev (10):CD010902

  12. Ghoreishi Z et al (2012) Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer 12:355

  13. Kato Y et al (2017) Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain. Proc Natl Acad Sci USA 114(31):E6297–E6305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Boehmerle W et al (2014) Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep 4:6370

  15. Staff NP et al (2020) Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol 324:113121

  16. Burgos E et al (2012) Cannabinoid agonist WIN 55,212–2 prevents the development of paclitaxel-induced peripheral neuropathy in rats Possible involvement of spinal glial cells. Eur J Pharmacol 682(13):62–72

    Article  CAS  PubMed  Google Scholar 

  17. Bennett GJ et al (2011) Terminal arbor degeneration - a novel lesion produced by the antineoplastic agent paclitaxel. Eur J Neurosci 33(9):1667–1676

    Article  PubMed  PubMed Central  Google Scholar 

  18. Pevida M et al (2013) Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia. Brain Res Bull 95:21–27

    Article  CAS  PubMed  Google Scholar 

  19. Wu J et al (2019) Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats. J Pain 20(5):501–514

    Article  CAS  PubMed  Google Scholar 

  20. Ba XY et al (2018) Cinobufacini protects against paclitaxel-induced peripheral neuropathic pain and suppresses TRPV1 up-regulation and spinal astrocyte activation in rats. Biomed Pharmacother 108:76–84

    Article  CAS  PubMed  Google Scholar 

  21. Takanashi K et al (2021) Gosha**kigan attenuates paclitaxel-induced neuropathic pain via cortical astrocytes. Pharmacol Res Perspect 9(6):e00850

  22. Ouellet M et al (2009) Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem Int 55(7):476–482

    Article  CAS  PubMed  Google Scholar 

  23. Hershman DL et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774

    Article  CAS  PubMed  Google Scholar 

  24. Loprinzi CL et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325–3348

Download references

Acknowledgements

We thank Bronwen Gardner, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Author information

Authors and Affiliations

  1. Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan

    Kozo Saito & Schuichi Koizumi

  2. Yamanashi GLIA Center, University of Yamanashi, Chuo, Yamanashi, Japan

    Kozo Saito & Schuichi Koizumi

Authors
  1. Kozo Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Schuichi Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors wrote and reviewed the manuscript.

Corresponding author

Correspondence to Schuichi Koizumi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

This article does not contain any studies with human participants or animals performed by the authors.

Informed consent

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saito, K., Koizumi, S. A promising drug for neuropathic pain: identification of vesicular nucleotide transporter as a novel target of eicosapentaenoic acid. Purinergic Signalling 19, 587–589 (2023). https://doi.org/10.1007/s11302-022-09918-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11302-022-09918-7

Search

Navigation